Alcon has abruptly taken its Cypass microstent off the global market due to problems with the five-year safety data. It found that endothelial cell loss (ECL) was greater with the microstent than in the cataract surgery-only control group. In the eye, these cells sit in the inner layer of the cornea to keep it dry and are crucial for maintaining fluid buildup and visual acuity. Read More
